[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-418047-105":59,"doc-detail-418047-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ten-years-in-remission-the-long-term-journey-of-a-breast-cancer-survivor","Ten Years in Remission - The Long-Term Journey of a Breast Cancer Survivor","","Metastatic breast cancer remains a challenging clinical entity, with long-term remission being rare. The case reports a 51-year-old woman diagnosed in 2009 with HER2-positive, hormone-receptor positive invasive carcinoma of the right breast and extensive hepatic metastases. After multimodal therapy—including surgery, multiple chemotherapy lines, targeted therapy, and hormonal therapy—complete remission was achieved in 2016 and sustained until death in 2025. In 2024, she developed a second primary gastric adenocarcinoma and treatment-related hepatic toxicity, highlighting the need for long-term surveillance.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ten-years-in-remission-the-long-term-journey-of-a-breast-cancer-survivor/418047/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ten-years-in-remission-the-long-term-journey-of-a-breast-cancer-survivor/418047.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",17,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why is long-term remission in metastatic breast cancer uncommon?","Question",{"text":113,"@type":114},"Long-term remission is rare because metastatic breast cancer typically has limited durable control. The introduction notes a global median survival of about 18–24 months despite advances in targeted therapies.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What treatments led to complete remission in this case?",{"text":118,"@type":114},"The patient received multimodal care: palliative chemotherapy (including FEC), a modified radical mastectomy, subsequent docetaxel and trastuzumab, and continued targeted/hormonal approaches, resulting in complete remission of metastatic disease in 2016.",{"name":120,"@type":111,"acceptedAnswer":121},"What complications occurred during long-term survival?",{"text":122,"@type":114},"Later complications included the development of a second primary gastric adenocarcinoma in 2024 and treatment-related hepatic toxicity. The article emphasizes the importance of long-term surveillance for secondary malignancies and late adverse effects.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},418047,1790794617,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":29,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Review began 09/03/2025  \nReview ended 10/16/2025  \nPublished 12/02/2025  \n© Copyright 2025  \nPeixoto et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0. , which permits unrestricted use , distribution , and reproduction in any medium , provided the original author and source are credited.  \nDOI: 10.7759/cureus.98291  \nOpen Access Case Report  \nTen Years in Remission: The Long-Term Journey of a Breast Cancer Survivor  \nSofia Peixoto 1 , Raquel Basto 1 , Enrique Dias 1  \n1. Department of Medical Oncology, Unidade Local de Saúde de Gaia e Espinho, E.P.E. (ULS Gaia-Espinho), Vila Nova de Gaia, PRT  \nCorresponding author: Sofia Peixoto, [sofpeixoto@gmail.com](sofpeixoto@gmail.com)  \nAbstract  \nMetastatic breast cancer (MBC) remains a challenging clinical entity, with long-term remission being rare. We report the case of a 51-year-old woman diagnosed in 2009 with HER2-positive, hormone receptorpositive invasive carcinoma of the right breast with extensive hepatic metastases. Following multimodal treatment, including surgery, multiple lines of chemotherapy, targeted therapy, and hormonal therapy, she achieved complete remission of metastatic disease in 2016 and remained disease-free until her death in 2025. Her clinical course was later complicated by the development of a second primary gastric adenocarcinoma in 2024, as well as treatment-related hepatic toxicity. This case illustrates that, in selected patients, prolonged remission can be achieved through a multidisciplinary, personalized treatment strategy and personalized approach. At the same time, it underscores the critical importance of long-term surveillance for secondary malignancies and late treatment-related adverse effects.  \nCategories: Therapeutics, Oncology  \nKeywords: her2+, long-term survival, metastatic breast cancer, palliative chemotherapy, personalized treatment, remission  \nIntroduction  \nMetastatic breast cancer (MBC) remains a major clinical challenge, with a global median survival of 18-24 months [1] . Advances in targeted therapies, particularly for HER2-positive (HER2+) subtypes, have transformed treatment paradigms, enabling durable responses and, in rare instances, prolonged remissions [1,2] . Studies suggest that up to 3% of cases may achieve long-term cure, particularly in younger individuals with oligometastatic disease who undergo aggressive multimodal treatment [2] . Survival beyond 10 years has been associated with factors such as hormone receptor positivity (ER+/PR+), HER2 positivity, absence of visceral metastases, and sustained responses to anti-HER2 therapies [2,3] . Nevertheless, long-lasting remission in MBC with extensive hepatic involvement remains exceptional.  \nThe literature indicates that durable disease control may be facilitated by prolonged benefit from combined regimens (e.g., lapatinib with endocrine therapy), local treatment of oligometastases, and molecular stability (such as absence of PI3K or ESR1 mutations) [2,3] . However, discontinuation of therapy in such contexts, whether due to cumulative toxicity or comorbidities, remains insufficiently studied, creating a therapeutic dilemma [2] .  \nThis case describes a patient with HER2+ MBC and multinodular hepatic metastasis who achieved and maintained clinical remission for 15 years under continuous palliative chemotherapy, challenging the traditional expectation of inevitable progression in visceral disease. The later development of a second primary gastric adenocarcinoma, in the absence of breast cancer recurrence, underscores the importance of multidisciplinary surveillance in long-term survivors, as well as dedicated follow-up programs tailored to monitor both late treatment effects and secondary malignancies.  \nThe patient 's outcome illustrates the value of a multidisciplinary strategy that integrates personalized systemic therapy with proactive management of adverse events, highlighting the interplay betwee","cbCaimNYsxiVlsLr","https://ap.wps.com/l/cbCaimNYsxiVlsLr","pdf",3026313,"English","# Abstract\n# Introduction\n# Case Presentation\n## Diagnosis and staging\n## Treatment course and follow-up\n# How to cite this article","[{\"question\":\"Why is long-term remission in metastatic breast cancer uncommon?\",\"answer\":\"Long-term remission is rare because metastatic breast cancer typically has limited durable control. The introduction notes a global median survival of about 18–24 months despite advances in targeted therapies.\"},{\"question\":\"What treatments led to complete remission in this case?\",\"answer\":\"The patient received multimodal care: palliative chemotherapy (including FEC), a modified radical mastectomy, subsequent docetaxel and trastuzumab, and continued targeted/hormonal approaches, resulting in complete remission of metastatic disease in 2016.\"},{\"question\":\"What complications occurred during long-term survival?\",\"answer\":\"Later complications included the development of a second primary gastric adenocarcinoma in 2024 and treatment-related hepatic toxicity. The article emphasizes the importance of long-term surveillance for secondary malignancies and late adverse effects.\"}]","Ten Years in Remission - The Long-Term Journey of a Breast Cancer Survivor | PDF",1790611751,15]